The Filing Desk

Lexaria Bioscience vs Seres Therapeutics

Lexaria Bioscience LEXX · Seres Therapeutics MCRB · Pharmaceuticals

Seres Therapeutics reported revenue of $1 million in fiscal 2025, about the same as Lexaria Bioscience's $1 million in fiscal 2025. Lexaria Bioscience had an operating margin of -1683.0%, against -11910.1% at Seres Therapeutics. Free cash flow was −$10 million at Lexaria Bioscience and $1 million at Seres Therapeutics. Their fiscal years end in different months (August 31 and December 31), so the periods don't line up exactly.

Side by side

Lexaria BioscienceSeres Therapeutics
Latest fiscal yearFY2025, Aug 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth52.0%—
Revenue growth a year, last 5 years18.5%−52.5%
Gross margin99.6%—
Operating margin−1,683.0%−11,910.1%
Net margin−1,686.0%721.9%
Free cash flow−$10M$1M
Free cash flow margin−1,483.9%109.6%
Return on capital−929.6%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count45.3%14.2%
Last close$4.49$1.33
P/E at the last close——
Insider trades, last 12 months—sold $10,043
Piotroski F-score3 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Lexaria BioscienceSeres Therapeutics
Operating margin
Percent of revenue
Lexaria BioscienceSeres Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lexaria BioscienceSeres Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lexaria Bioscience and Seres Therapeutics pages.